Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 18/20 | 0.49 |
| ▸ | SCN7A | Q01118 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923306 | 0.93 | PTGES (0.52) | PTGESSCN9ASCN7AKCNH2SCN5A | |
| SCHEMBL4228507 | 0.89 | SCN9A (0.48) | PTGESSCN9ASCN10A | |
| Water SCHEMBL4923358 | 0.87 | PTGES (0.66) | PTGESSCN9A | |
| Water SCHEMBL4923346 | 0.87 | PTGES (0.66) | PTGESSCN9A | |
| SCHEMBL3582187 | 0.85 | PTGES (0.67) | PTGES | |
| Hydrochloric Acid SCHEMBL4218099 | 0.85 | SCN9A (0.56) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL4095174 | 0.84 | PTGES (0.51) | PTGES | |
| SCHEMBL4233483 | 0.83 | SCN9A (0.47) | PTGESSCN9ASCN7AKCNH2SCN5A | |
| SCHEMBL4089205 | 0.83 | PTGES (0.56) | PTGESSCN9A | |
| SCHEMBL4921606 | 0.83 | PTGES (0.61) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | PTGES 35/4885SCN9A 4095/4885SCN7A 4261/4885 |
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | PTGES 28/4885SCN9A 4230/4885SCN7A 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.